Cadent Therapeutics, Inc.

Thomas Amos Jacobsen

Gregg F Keaney

Martin R Jefson

Janus Schreiber Larsen

Karin Sandager Nielsen

Dipak Vasantrao Amrutkar

Kelly Foster

John Adams Lowe, Iii

John Michael McCall

Birgitte Langer Eriksen

Charlotte Hougaard

Dorte Strøbæk

Magnus Gustafsson

Nadia Lybøl Von Schoubye

Jessica Klein

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels. 

Potassium channel modulators

Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.

Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).

Growing community of inventors

Oested, Denmark

Thomas Amos Jacobsen